New COPD drug wins backing of US FDA panel advisers

Published: 2012-02-28 06:56:00

Updated: 2012-02-28 06:56:00

The U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee (PADAC) on Feb. 24 voted 12 to 2 in favor of approving the New Drug Application (NDA) for Spain based Almirall’s aclidinium bromide, a new long-acting antimuscarinic for the maintenance treatment of COPD, accoridng...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK